{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '39', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Posttreatment', 'Notes', 'Safety', 'Survival', 'Treatment', 'Follow-', 'Follow-', 'Follow-', 'All procedures are to', 'Study Period', 'Screening', 'Cycle = 21 Days', 'EOT', 'up', 'up', 'up', 'be performed before', '30 Days', 'study intervention', 'At', '-28 to -1', '1', '2', '3', '4', '6 to 35', 'Every', 'Every', 'Visit Timing/', '5', 'DC', 'post last', 'administration unless', '12 weeks', '12 weeks', 'Cycle Number', 'dose', 'otherwise indicated.', 'Cycle Day', 'Refer to Section 8.11', '(=3 days unless', '1', '8', '15', '1', '15', '1', '1', '1', '1', 'for visit details.', 'otherwise specified)', 'Scheduling Window', '+3', '3', '3', '3', '3', '3', '3', '3', '3', '+7', ' 7', '14', '(Days)', 'At Screening, C2D1,', 'then every 2 cycles', 'thereafter.', '-Screening samples to be', 'collected within 10 days', 'before first dose.', '-Participants may be', 'dosed in subsequent', 'cycles after C1D1 while', 'Thyroid function', 'X', 'X', 'X', 'X', 'X', 'X', '(T3, T4, and TSH)', 'thyroid function tests are', 'pending.', '- -After C1, collect within', '3 days before dosing.', '-Free T3 and Free T4 are', 'acceptable.', '-May use central', 'laboratory only if local', 'laboratory is not', 'capable.', 'Biomarkers: Analysis by Central Laboratory', 'Blood for genetic', 'X', '-Collect before study', 'analysis', 'intervention.', 'Abbreviations: AE = adverse event; ALK = anaplastic lymphoma kinase gene; ANC = absolute neutrophil count; aPTT = activated partial thromboplastin time; BP = blood', 'pressure; CT = computed tomography; CXDY= Cycle X Day Y; DC = discontinuation; ECG = electrocardiogram; ECHO = echocardiogram; ECOG = Eastern Cooperative', 'Oncology Group; EGFR = epidermal growth factor receptor; EOT = end of treatment; ePRO = electronic patient-reported outcome; FSH = follicle-stimulating hormone;', 'FT3 = free triiodothyronine; FT4 = free thyroxine; \u00df-HCG = \u00df human chorionic gonadotropin; HIV = human immunodeficiency virus; ICF = informed consent form;', 'INR = international normalized ratio; IV = intravenous; K-ras = Kirsten rat sarcoma oncogene; MRI = magnetic resonance imaging; MUGA = multigated acquisition;', 'PD = progressive disease; PD-L1 = programmed cell death ligand 1; PK = pharmacokinetic(s); PO = bral(ly); PT = prothrombin time; PTT = partial thromboplastin time;', 'QXW = every X weeks; QD = once daily; ROSI = ROS proto-oncogene 1; SAE = serious adverse event; ; T3 = triiodothyronine; T4 = thyroxine; WOCBP = women of', 'childbearing potential; SoA = schedule of activities; SOC = standard of care.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '40', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '1.3.2', 'Second-course Treatment Phase', 'NOTE: As of Amendment 007-06, the Second-course Treatment Phase has been removed from the study.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}